Key result
Higher plateletcrit on admission was an independent predictor of no-reflow during saphenous vein graft PCI in patients with NSTEMI.
Why the study?
Plateletcrit is associated with cardiovascular outcomes, but whether it can predict no-reflow in NSTEMI patients undergoing PCI for saphenous vein graft disease was unknown.
Does plateletcrit on admission predict the development of no-reflow in patients with NSTEMI undergoing PCI for SVG disease?
Observational (n=181)
Does plateletcrit on admission predict the development of no-reflow in patients with NSTEMI undergoing PCI for SVG disease?
Answers are grounded in this paper and cite their sources.
Higher plateletcrit on admission is an independent predictor of no-reflow phenomenon during saphenous vein graft PCI in NSTEMI patients.
Saphenous vein graft (SVG) percutaneous coronary interventions (PCIs) are procedures with potential complications such as distal embolization, slow or no-reflow phenomenon. Platelets are the main factors in development of thrombus and no-reflow phenomenon. There have been multiple studies that identified the association between plateletcrit (PCT) and cardiovascular outcomes. The aim of the study was to investigate whether PCT can predict the development of no-reflow in patients with non-ST elevation myocardial infarction (NSTEMI) undergoing PCI for SVG disease. A total of 181 patients who underwent PCI for SVG disease with NSTEMI were included retrospectively. Platelet indices on admission were recorded. Patients were divided into two groups according to the development of no-reflow during the procedure: no-reflow (n = 32; 18%) and normal reflow (n = 149; 82%). PCT and platelet count were higher in the no-reflow group (0.254 vs. 0.224, P = 0.020; 265.4 vs. 233, P = 0.011, respectively). The PCT cut-off value for predicting no-reflow was calculated as 0.230 by ROC curve analysis with 68.8% sensitivity and 51.0% specificity. Multivariate logistic regression analysis showed that PCT was an independent predictor of no-reflow (odds ratio: 5.091, confidence interval: 1.356-19.116, P = 0.016). PCT may be useful in identifying patients at risk for developing no-reflow in patient with NSTEMI undergoing SVG PCI.
No takes yet. Share an insight, caveat, or question.
Panç et al. (2021) conducted an observational in NSTEMI undergoing PCI for SVG disease (n=181). Plateletcrit (PCT) was evaluated on Development of no-reflow during the procedure (OR 5.091, 95% CI 1.356-19.116, p=0.016). Higher plateletcrit on admission was an independent predictor of no-reflow during saphenous vein graft PCI in patients with NSTEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: